A telemedicine provider is now making GLP-1 medications available to assist in treating addiction. Originally approved for managing type 2 diabetes and obesity, GLP-1 drugs are increasingly attracting attention for their potential role in addressing substance use disorders via telehealth platforms.
This initiative accompanies other major public health developments, including structural changes to COVID-19 operations at the Centers for Disease Control and Prevention (CDC) and ongoing measurements of public confidence in Dr. Anthony Fauci.
Source Attribution: Article content originally reported by Theresa Gaffney. Read original story coverage on Theresa Gaffney →
